CrystalGenomics, Inc.

Quick facts

Phase 3 pipeline

• CG100649 · Immunology
  CG100649 is a selective inhibitor of cathepsin S that reduces inflammatory responses by modulating immune cell activation and antigen presentation.

Phase 2 pipeline

• CG400549 · Oncology, Neurology
  CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses.

Phase 1 pipeline

• CG-549
• CG-745 IV Solution
• CG1801
• CG200745
• CG200745 PPA
• CGL1802
• Polmacoxib and Tramadol combination

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CrystalGenomics, Inc. portfolio CI brief
• CrystalGenomics, Inc. pipeline updates RSS